Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Zynerba Pharmaceuticals, Inc. To Contact The Firm
Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Zynerba Pharmaceuticals, Inc. (“Zynerba” or the “Company”) (NASDAQ: ZYNE) of the December 23, 2019 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
If you invested in Zynerba stock or options between March 11, 2019 and September 17, 2019 and would like to discuss your legal rights, please fill out the form below. There is no cost or obligation to you.You can also contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to email@example.com.
The lawsuit has been filed in the U.S. District Court for the Eastern District of Pennsylvania on behalf of all those who purchased Zynerba securities between March 11, 2019 and September 17, 2019 (the “Class Period”). The case, Velayos v. Zynerba Pharmaceuticals, Inc. et al., No. 19-cv-04959 was filed on October 23, 2019, and has been assigned to Judge Nitza I. Quinones Alejandro.
The lawsuit focuses on whether the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) Zygel was proving unsafe and not well-tolerated in the BELIEVE 1 Trial; (2) the foregoing created a foreseeable, heightened risk that Zynerba would fail to secure the necessary regulatory approvals for commercializing Zygel for the treatment of developmental and epileptic encephalopathies (“DEE”) in children and adolescents; and (3) as a result, the Company’s public statements were materially false and misleading at all relevant times.
On September 18, 2019, during pre-market hours, Zynerba issued a press release announcing results from the BELIEVE 1 Trial evaluating topical gel Zygel in children and adolescents with DEE. While Zynerba asserted that Zygel was well-tolerated in the September 2019 Press Release, it also disclosed that, among patients enrolled in the BELIEVE 1 Trial, the rate of treatment emergent adverse event (“TEAEs”) was 96%, the rate of treatment related adverse events (“TRAEs”) was 60%, and there were ten patients who reported serious adverse events (“SAEs”), of which, “two SAEs (lower respiratory tract infection and status epilepticus) were determined to be possibly related to treatment.”
On this news, Zynerba’s stock price fell from $11.30 per share on September 17, 2019 to $8.84 per share on September 18, 2019—a $2.46 or 21.77% drop.
Zynerba Pharmaceuticals, Inc. (ZYNE)
* The submission of this form does not create an attorney-client relationship.
Filed on 11/04/2019
Lead Plaintiff Deadline 12/23/2019
685 Third Avenue 26th Floor
10017 New York, New York
Phone (212) 983-9330
Fax (212) 983-9331
Richard W. Gonnello firstname.lastname@example.org Phone (212) 983-9330 Fax (212) 983-9331